[receptor] on the CD28 positive T cells with the soluble B7 protein and thereby inhibiting T cell proliferation.

--~~80~~. (Amended) The method of claim ~~79~~, wherein the soluble B7 fusion protein has an amino acid sequence containing amino acid residues from about position 1 to about position 215 of the amino acid sequence corresponding to the extracellular domain of B7 [antigen] which recognizes and binds the CD28 positive T cells.

--~~81~~. (Amended) The method of claim ~~79~~, wherein the soluble B7 fusion protein comprises a fusion polypeptide having a first amino acid sequence corresponding to the extracellular domain of B7 [antigen] which recognizes and binds [the] CD28 [antigen] and a second amino acid sequence corresponding to a moiety that alters the solubility, affinity, and/or valency of the soluble B7 fusion protein for binding to [the] CD28 [receptor].

--~~84~~. (Amended) The method of claim ~~79~~, wherein the soluble B7 fusion protein comprises a fusion polypeptide having a first amino acid sequence containing amino acid residues from about position 1 to about position 215 of the amino acid sequence corresponding to the extracellular domain of the soluble B7 fusion protein which recognizes and binds [the] CD28 [antigen] and a second amino acid sequence corresponding to the hinge, CH2, and CH3 regions of human immunoglobulin Cγ1.

--~~85~~. (Amended) A method for inhibiting [preventing] the binding of [the] CD28 positive T cells [receptor] to [a] B7 positive B cells [antigen] comprising contacting the CD28 positive T cells with a soluble B7 fusion protein which recognizes and

binds [the] CD28 [receptor] on the CD28 positive T cells thereby preventing binding of CD28 [the receptor] to the B7 positive B cells [antigen].

--~~86~~. (Amended) The method of claim ~~85~~, wherein the soluble B7 fusion protein is a B7Ig fusion protein comprising an amino acid sequence containing amino acid residues from about position 1 to about position 215 of the amino acid sequence corresponding to the extracellular domain of [the] B7 [antigen] which recognizes and binds CD28.--

--~~87~~. (Amended) The method of claim ~~86~~, wherein the fusion protein is B7Ig fusion protein [corresponding to] having the amino acid sequence encoded by DNA contained in the plasmid having ATCC No. 68627.

--~~88~~. (Amended) A method of inhibiting CD28 positive T cell [activation] responses comprising reacting B7 positive B cells with a soluble CD28 fusion protein so as to bind the B7 positive B cells with the soluble CD28 fusion protein thereby inhibiting T cell [activation] responses.

--~~89~~. (Amended) The method of claim ~~88~~, wherein the soluble CD28 fusion protein comprises a polypeptide having an amino acid sequence containing amino acid residues from about position 1 to about position 134 of the amino acid sequence corresponding to the extracellular domain of CD28 [receptor].

--~~90~~. (Amended) The method of claim ~~89~~, wherein the soluble CD28 fusion protein has a first amino acid sequence corresponding to the extracellular domain of CD28 [receptor] and a second amino acid sequence corresponding to a moiety that alters

K2

the solubility, affinity, and/or valency of the CD28 [receptor] for binding to B7 positive B cells [antigen].

--93. ~~88~~ 15 (Amended) The method of claim ~~88~~ 10, wherein the soluble CD28 fusion protein comprises a polypeptide having a first amino acid sequence containing amino acid residues from about position 1 to about position 134 of the amino acid sequence corresponding to the extracellular domain of CD28 [receptor] and a second amino acid sequence corresponding to the hinge, CH2, and CH3 regions of human immunoglobulin Cγ1.

--~~94~~. 16 (Amended) The method of claim ~~93~~ 15, wherein the fusion protein is CD28Ig fusion protein [corresponding to] having the amino acid sequence encoded by DNA contained in the plasmid having ATCC No. 68628.

K3

--95. (Amended) A method for inhibiting [preventing] the binding of the B7 positive B cells [receptor] to a CD28 positive T cells [antigen] comprising contacting B7 positive cells with a soluble CD28 fusion protein which recognizes and binds [the] B7 [receptor] on the B7 positive cells thereby preventing binding of the B7 positive B cells [receptor] to the CD28 positive T cells [antigen].

--96. (Amended) The method of claim 95, wherein the soluble CD28 fusion protein is a CD28Ig fusion protein comprising an amino acid sequence containing amino acid residues from about position 1 to about position 134 of the amino acid sequence corresponding to the extracellular domain of [the] CD28 [receptor] which recognizes and binds [the] B7 [antigen].